Kura Oncology (NASDAQ:KURA) Trading Down 2.3%

Shares of Kura Oncology, Inc. (NASDAQ:KURA) dropped 2.3% on Tuesday . The company traded as low as $20.33 and last traded at $20.39. Approximately 12,316 shares were traded during trading, a decline of 99% from the average daily volume of 952,298 shares. The stock had previously closed at $20.87.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Stifel Nicolaus cut their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday, August 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $30.60.

Kura Oncology Trading Up 0.5 %

The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $20.30 and a 200 day simple moving average of $20.63. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -9.34 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the previous year, the business posted ($0.53) earnings per share. The firm’s quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts predict that Kura Oncology, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in Kura Oncology during the first quarter valued at $110,000. Cape Investment Advisory Inc. acquired a new position in Kura Oncology in the fourth quarter valued at approximately $176,000. Quarry LP purchased a new stake in Kura Oncology in the 2nd quarter worth approximately $196,000. Saxon Interests Inc. acquired a new stake in shares of Kura Oncology during the 1st quarter worth approximately $201,000. Finally, Entropy Technologies LP purchased a new position in shares of Kura Oncology during the 1st quarter valued at approximately $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.